We are live on ! Find out more
JANX icon

Janux Therapeutics
JANX

160 hedge funds and large institutions have $2.07B invested in Janux Therapeutics in 2024 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 56 increasing their positions, 49 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

19% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 27

14% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 49

11% more capital invested

Capital invested by funds: $1.87B → $2.07B (+$199M)

3% more funds holding

Funds holding: 155 → 160 (+5)

1.21% more ownership

Funds ownership: 86.26% → 87.46% (+1.2%)

86% less call options, than puts

Call options by funds: $4.14M | Put options by funds: $29.8M

Holders
160
Holders Change
+5
Holders Change %
+3.23%
% of All Funds
2.3%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
32
Increased
56
Reduced
49
Closed
27
Calls
$4.14M
Puts
$29.8M
Net Calls
-$25.6M
Net Calls Change
-$25.3M

Top Buyers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
+$56.5M
2
PBA
Paradigm Biocapital Advisors
New York
+$36.4M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$31.4M
4
NNPTE
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne
Poland
+$20.5M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$12.4M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$74.9M
2
Citadel Advisors
Citadel Advisors
Florida
-$23.8M
3
BI
BVF Inc
California
-$18.5M
4
SC
Samlyn Capital
New York
-$13.6M
5
APM
Avidity Partners Management
Texas
-$12.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
GTC
26
Ghost Tree Capital
New York
$8.63M +$6.09M +140,000 +280%
Barclays
27
Barclays
United Kingdom
$7.91M +$6.3M +144,883 +497%
MB
28
MPM BioImpact
Massachusetts
$7.77M +$7.44M +171,105 New
N
29
Nuveen
North Carolina
$7.58M -$10M -230,014 -58%
SI
30
Sofinnova Investments
California
$7.49M +$7.17M +164,770 New
T. Rowe Price Associates
31
T. Rowe Price Associates
Maryland
$7.24M -$4.04M -92,937 -37%
SSA
32
Schonfeld Strategic Advisors
New York
$6.79M -$4.05M -93,176 -38%
Morgan Stanley
33
Morgan Stanley
New York
$6.38M +$2.55M +58,666 +72%
CS
34
Candriam SCA
Luxembourg
$6.23M +$1.09M +25,101 +22%
Ensign Peak Advisors
35
Ensign Peak Advisors
Utah
$6.04M – – –
Hudson Bay Capital Management
36
Hudson Bay Capital Management
Connecticut
$5.62M +$5.38M +123,658 New
ABG
37
Ally Bridge Group
New York
$4.94M +$4.73M +108,811 New
RPAM
38
Rhenman & Partners Asset Management
Sweden
$4.85M – – –
Bank of New York Mellon
39
Bank of New York Mellon
New York
$3.94M -$1.23M -28,192 -25%
D.E. Shaw & Co
40
D.E. Shaw & Co
New York
$3.82M -$602K -13,834 -14%
BOCH
41
Blue Owl Capital Holdings
New York
$3.63M +$1.74M +40,000 +100%
Two Sigma Investments
42
Two Sigma Investments
New York
$3.51M -$1.15M -26,409 -25%
Macquarie Group
43
Macquarie Group
Australia
$3.48M – – –
Schroder Investment Management Group
44
Schroder Investment Management Group
United Kingdom
$3.44M +$1.7M +39,092 +111%
VOYA Investment Management
45
VOYA Investment Management
Georgia
$3.17M +$401K +9,223 +15%
Rafferty Asset Management
46
Rafferty Asset Management
New York
$2.98M -$503K -11,556 -15%
EFM
47
E Fund Management
China
$2.96M +$2.83M +65,098 New
Balyasny Asset Management
48
Balyasny Asset Management
Illinois
$2.87M +$2.75M +63,215 New
Bank of America
49
Bank of America
North Carolina
$2.85M -$2.46M -56,596 -47%
Susquehanna International Group
50
Susquehanna International Group
Pennsylvania
$2.53M +$1.31M +30,014 +117%
1
2
3 4 5

JANX Hedge Fund Activity: Q3 2024 in Review

160 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q3 2024, worth a combined $2.07B — up 11% from $1.87B a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new JANX positions and 27 closed out — a net gain of 5 holders — while 56 added to existing stakes and 49 trimmed.

The largest buyer was Woodline Partners, adding an estimated $56.5M. The largest seller was OrbiMed, cutting an estimated $74.9M.

  • 160 institutional investors held Janux Therapeutics (JANX) as of Q3 2024, up from 155 in Q2 2024.
  • Funds reported $2.07B of Janux Therapeutics stock for Q3 2024, up 11% quarter-over-quarter.
  • 32 funds opened new Janux Therapeutics positions in Q3 2024 and 27 closed out, a net change of +5 holders.
  • The largest Janux Therapeutics buyer in Q3 2024 was Woodline Partners, an estimated $56.5M added.
  • The largest Janux Therapeutics seller in Q3 2024 was OrbiMed, an estimated $74.9M sold.

Based on aggregated 13F filings for Q3 2024.